Prajna NV, Radhakrishnan N, Lalitha P, et al. - In this outcome-masked, randomized controlled clinical trial, researchers sought to determine whether there is a benefit to adjuvant corneal cross-linking (CXL) for bacterial keratitis. Patients who presented with a smear-positive bacterial ulcer at Aravind Eye Hospitals in Madurai, Pondicherry, and Coimbatore in India were included in the study. The study eyes were randomly assigned to receive either topical moxifloxacin 0.5% or topical moxifloxacin 0.5% plus CXL. Adjuvant CXL therapy was not found to be beneficial in the primary treatment of moderate bacterial keratitis. CXL, on the other hand, may reduce culture positivity and complication rates; thus, a larger trial to fully evaluate this is required.